Previous close | 2.8500 |
Open | 2.8900 |
Bid | 2.6700 |
Ask | 2.9800 |
Strike | 141.00 |
Expiry date | 2024-07-12 |
Day's range | 2.8900 - 2.8900 |
Contract range | N/A |
Volume | |
Open interest | 53 |
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo Nordisk announced results from the phase 3 FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) w
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.
Oppenheimer analyst Jay Olson spent several days last week listening as companies such as Eli Lilly discussed how to improve on blockbusters like Zepbound and Novo Nordisk’s Wegovy.